SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Eisai Corporation of North America today announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in ...

MINNEAPOLIS--(BUSINESS WIRE)--Aug. 1, 2006--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that the European Medicines Agency (EMEA) ...

DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released ...

Patients with myeloproliferative neoplasm (MPN) may benefit from this combination treatment if they are in the accelerated or blast phase of the disease. Results from a phase 2 study demonstrated that ...

WOODCLIFF LAKE, N.J., July 1, 2008 Eisai Corporation ofNorth America today announced the preliminary efficacy data from a trialinitiated in 2002 comparing Dacogen(R) (decitabine) to Best Supportive ...

The Food and Drug Administration approved the oral combination of Inquovi (Dacogen [decitabine] and cedazuridine) for certain adult patients with myelodysplastic syndromes (MDS). The Food and Drug ...

Dublin-based SuperGen and MGI Pharma Inc. said U.S. regulators approved the companies’ Dacogen treatment, the third drug to win approval for treating a group of fatal blood and bone-marrow disorders.

Johnson & Johnson has garnered expanded approvals from Europe's regulator for two of its cancer treatments. Johnson & Johnson has garnered expanded approvals from Europe’s regulator for two of its ...

Most news items about Astex Pharmaceuticals (NAS: ASTX) focus on the company's profitable drug Dacogen. However, on Monday the company announced movement in its pipeline beyond Dacogen. A phase 1 ...

Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen ®. In addition, Otsuka has acquired licensing rights worldwide, ...

With approval of Dacogen (decitabine), the injectable drug for myelodysplastic syndromes from MGI Pharma Inc. and SuperGen Inc. expected May 15, analysts continue to weigh the compound’s chances ...

DACOGEN was administered at 20 mg/m 2 as a 1-hour intravenous infusion once daily for five consecutive days, repeated every four weeks, continued as long as the patient derived benefit. Key results ...